Vol 17, No 6 (2021)
Review paper
Published online: 2021-12-30

open access

Page views 5682
Article views/downloads 563
Get Citation

Connect on Social Media

Connect on Social Media

Desensitization in patients hypersensitive to platinum compounds in gynecologic oncology

Joanna Stanisławiak-Rudowicz1, Anita Chudecka-Głaz2, Małgorzata Jazel3, Radosław Mądry4
Oncol Clin Pract 2021;17(6):263-270.

Abstract

The treatment of ovarian cancer based on platinum analogs has taken on a new and additional importance in recent years. The introduction of modern maintenance therapy — PARP inhibitors — has significantly prolonged the time to progression in recurrent and newly diagnosed ovarian cancer and clinically meaningful, as per SOLO-2 results, prolonging overall survival in recurrent disease. This is an absolute breakthrough in the treatment of advanced forms of this cancer. Sensitivity to platinum is a prerequisite for the efficacy of this therapy as well as patient eligibility for treatment. Hypersensitivity issues can significantly limit access to this modern and effective maintenance therapy. Platinum hypersensitivity usually occurs in subsequent lines of therapy and with subsequent cycles of treatment. Hypersensitivity reactions cannot always be predicted, despite known risk factors. In order to maintain platinum-based treatment, we can modify premedication modalities, but appropriate desensitization protocols seem to be most effective. This article describes the most commonly used desensitization methods in patients with ovarian cancer and platinum hypersensitivity in a practical way, e.g., as they are used in the centers where the authors of this publication practice.

Article available in PDF format

View PDF Download PDF file

References

  1. Colombo N, Moore K, Scambia G, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018; 379(26): 2495–2505.
  2. Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017; 18(9): 1274–1284.
  3. González-Martín A, Pothuri B, Vergote I, et al. PRIMA/ENGOT-OV26/GOG-3012 Investigators. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019; 381(25): 2391–2402.
  4. Mirza MR, Monk BJ, Herrstedt J, et al. ENGOT-OV16/NOVA Investigators. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016; 375(22): 2154–2164.
  5. Poveda A, Floquet A, Ledermann J, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021; 22(5): 620–631.
  6. Demoly P, Adkinson NF, Brockow K, et al. International Consensus on drug allergy. Allergy. 2014; 69(4): 420–437.
  7. Demoly P, Bousquet J. Drug allergy diagnosis work up. Allergy. 2002; 57 Suppl 72: 37–40.
  8. Lipp HP, Hartmann JT, Hartmann JT, et al. Toxicity of platinum compounds. Expert Opin Pharmacother. 2003; 4(6): 889–901.
  9. Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol. 2003; 24(3): 253–262.
  10. Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist. 2008; 13(6): 725–732.
  11. Boulanger J, Boursiquot JN, Cournoyer G, et al. Comité de l’évolution des pratiques en oncologie. Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations. Curr Oncol. 2014; 21(4): e630–e641.
  12. Demoor PA, Matusov Y, Kelly C, et al. A retrospective review of the frequency and nature of acute hypersensitivity reactions at a medium-sized infusion center: comparison to reported values and inconsistencies found in literature. J Cancer. 2011; 2: 153–164.
  13. Makrilia N, Syrigou E, Kaklamanos I, et al. Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs. 2010; 2010.
  14. Navo M, Kunthur A, Badell ML, et al. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients. Gynecol Oncol. 2006; 103(2): 608–613.
  15. Shukunami K, Kurokawa T, Kawakami Y, et al. Hypersensitivity reactions to intraperitoneal administration of carboplatin in ovarian cancer: the first report of a case. Gynecol Oncol. 1999; 72(3): 431–432.
  16. Gobel BH. Chemotherapy-induced hypersensitivity reactions. Oncol Nurs Forum. 2005; 32(5): 1027–1035.
  17. Markman M, Moon J, Wilczynski S, et al. Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial. Gynecol Oncol. 2010; 116(3): 323–325.
  18. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010; 28(20): 3323–3329.
  19. Joly F, Ray-Coquard I, Fabbro M, et al. Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial. Gynecol Oncol. 2011; 122(2): 226–232.
  20. Kook H, Kim KM, Choi SH, et al. Life-threatening carboplatin hypersensitivity during conditioning for autologous PBSC transplantation: successful rechallenge after desensitization. Bone Marrow Transplant. 1998; 21(7): 727–729.
  21. Markman M, Kennedy A, Webster K, et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol. 1999; 17(4): 1141.
  22. Sliesoraitis S, Chikhale PJ. Carboplatin hypersensitivity. Int J Gynecol Cancer. 2005; 15(1): 13–18.
  23. Hoekstra AV, Hurteau JA, Kirschner CV, et al. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer. Gynecol Oncol. 2009; 115(3): 377–381.
  24. Sugimoto H, Iwamoto T, Murashima Y, et al. Risk factors contributing to the development of carboplatin-related delayed hypersensitivity reactions in Japanese patients with gynecologic cancers. Cancer Chemother Pharmacol. 2011; 67(2): 415–419.
  25. Markman M, Zanotti K, Kulp B, et al. Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity. Gynecol Oncol. 2003; 89(3): 514–516.
  26. Gadducci A, Tana R, Teti G, et al. Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. Int J Gynecol Cancer. 2008; 18(4): 615–620.
  27. Simons FE, Ardusso LRF, Bilò MB, et al. World Allergy Organization. World allergy organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ J. 2011; 4(2): 13–37.
  28. Roselló S, Blasco I, Fabregat LG, et al. Corrections to “Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines”. Ann Oncol. 2018; 29: iv260.
  29. Garcia A, Frahm C, Jeter J, et al. Incidence of hypersensitivity reactions to carboplatin or paclitaxel in patients with ovarian, Fallopian tube, or primary peritoneal cancer with or without BRCA1 or BRCA2 mutations. J Clin Oncol. 2018; 36(15_suppl): e18758–e18758.
  30. Schwartz JR, Bandera C, Bradley A, et al. Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital. Gynecol Oncol. 2007; 105(1): 81–83.
  31. Moon DH, Lee JM, Noonan AM, et al. Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions. Br J Cancer. 2013; 109(4): 1072–1078.
  32. Altwerger G, Florsheim EB, Menderes G, et al. Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer. J Cancer Res Clin Oncol. 2018; 144(12): 2449–2456.
  33. Jerzak KJ, Deghan Manshadi S, Ng P, et al. Prevention of carboplatin-induced hypersensitivity reactions in women with ovarian cancer. J Oncol Pharm Pract. 2018; 24(2): 83–90.
  34. Metcalfe DD, Peavy RD, Gilfillan AM, et al. Understanding the mechanisms of anaphylaxis. Curr Opin Allergy Clin Immunol. 2008; 8(4): 310–315.
  35. Gleich GJ, Leiferman KM. Anaphylaxis: implications of monoclonal antibody use in oncology. Oncology (Williston Park). 2009; 23(2 Suppl 1): 7–13.
  36. Vultaggio A, Castells MC. Hypersensitivity reactions to biologic agents. Immunol Allergy Clin North Am. 2014; 34(3): 615–32, ix.
  37. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf (7.02.2020).
  38. Zweizig S, Roman LD, Muderspach LI. Death from anaphylaxis to cisplatin: a case report. Gynecol Oncol. 1994; 53(1): 121–122.
  39. Dizon DS, Sabbatini PJ, Aghajanian C, et al. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol. 2002; 84(3): 378–382.
  40. Polyzos A, Tsavaris N, Kosmas C, et al. Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology. 2001; 61(2): 129–133.
  41. Gammon D, Bhargava P, McCormick MJ, et al. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer. 2004; 100(1): 211–212.
  42. Syrigou E, Triantafyllou O, Makrilia N, et al. Acute hypersensitivity reactions to chemotherapy agents: an overview. Inflamm Allergy Drug Targets. 2010; 9(3): 206–213.
  43. O'Cearbhaill R, Zhou Q, Iasonos A, et al. The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment. Gynecol Oncol. 2010; 116(3): 326–331.
  44. Ottaiano A, Tambaro R, Greggi S, et al. Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma. Anticancer Research. 2003; 23(4): 3465–3468.
  45. Lee CW, Matulonis UA, Castells MC. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol. 2005; 99(2): 393–399.
  46. Castells M. Drug Desensitization in Oncology: Chemotherapy Agents and Monoclonal Antibodies. In: Pichler WJ. ed. Drug hypersensitivity. Karger, Basel 2007: 404–413.
  47. Colombo N, Sessa C, du Bois A, et al. ESMO-ESGO Ovarian Cancer Consensus Conference Working Group. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. Ann Oncol. 2019; 30(5): 672–705.
  48. Breslow RG, Caiado J, Castells MC. Acetylsalicylic acid and montelukast block mast cell mediator-related symptoms during rapid desensitization. Ann Allergy Asthma Immunol. 2009; 102(2): 155–160.
  49. Ang WX, Church AM, Kulis M, et al. Mast cell desensitization inhibits calcium flux and aberrantly remodels actin. J Clin Invest. 2016; 126(11): 4103–4118.
  50. Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 2008; 122(3): 574–580.